Pathogenesis of Alzheimer's disease.
Alzheimer's disease (AD) is incredibly common. Increasing longevity ensures its prevalence will rise even further. Ongoing efforts to understand AD pathogenesis reveal numerous tantalizing leads. Formulating a comprehensive AD pathogenesis theory capable of incorporating these disparate leads, though, has proven difficult. This review discusses current attempts to formulate a comprehensive AD pathogenesis theory. In doing so, it focuses on clinical and molecular relationships between AD and aging. A better understanding of these relationships could inform and impact future development of AD-directed treatment strategies.
Department of Neurology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA. rhs7e@virginia.edu
Russell H
RH
Swerdlow
D000375:Aging / Q000378:metabolism / Q000473:pathology; D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D023582:Alzheimer Vaccines; D000818:Animals; D001921:Brain / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D004272:DNA, Mitochondrial / Q000378:metabolism; D006801:Humans; D008928:Mitochondria / Q000378:metabolism; D009410:Nerve Degeneration / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D018696:Neuroprotective Agents / Q000627:therapeutic use; D018697:Nootropic Agents / Q000627:therapeutic use; D018384:Oxidative Stress; D058225:Plaque, Amyloid / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome
D023582:Alzheimer Vaccines; D004272:DNA, Mitochondrial; D018696:Neuroprotective Agents; D018697:Nootropic Agents